Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure BioSciences has high hopes for Phasex Corporation collaboration on UST tech

Pressure BioSciences revealed on Wednesday it was to collaborate with Phasex Corporation
Pressure BioSciences has high hopes for Phasex Corporation collaboration on UST tech
There is a rapidly expanding market for non-psychoactive extracts of cannabis plant material

Pressure BioSciences Inc (OTCMKTS:PBIO) is to collaborate with Phasex Corporation to combine its  exciting ultra shear technology (UST) with the latter's processing methods to develop water-soluble nanoemulsions.

These (nanoemulsions) are mixtures of two or more liquids, which could be used in various products, including  medical, pharmaceuticals, and nutraceuticals, and the companies hope to create a CBD-enriched plant oil.

As reported earlier this month, the UST technology was recently issued its first two patents in China.

"Following discussions with our colleagues at PBI, we believe the UST platform can be scaled to a cost-effective, commercially-viable level," Hans Schonemann, the president of Phasex, one of the world's most experienced supercritical fluid (SCF)-based toll processors.

"This would allow production of large quantities of stable, water-soluble nanoemulsions of compounds that were previously water-insoluble, such as CBD from cannabis.

"Such aqueous nanoemulsions could significantly increase the absorption and bioavailability of CBD and other previously water-insoluble compounds, which we believe would subsequently result in significant increases in their commercial demand."

Richard Schumacher, the chief executive and president at Pressure BioSciences, added: "We believe the ability to subject liquids to UST following the Phasex SCF extraction and purification process would be a highly sought-after "Value-add" for Phasex customers.

"Rapidly expanding markets for non-psychoactive extracts of cannabis plant material, for instance, is an example of a potentially high demand application for our combined, synergistic technologies.

"Oral bioavailability of CBD in aqueous emulsions has been previously demonstrated in several studies. Combining the capabilities and experience of PBI and Phasex could effectuate commercial scale production of such formulations with long shelf stability, which in turn could potentially result in a highly profitable service model for the PBI and Phasex collaboration."

UST is based on using intense shear forces generated from ultra-high pressure valve discharge - greater than 20,000 psi (pound per square inch).

Join our Crypto, Blockchain and Cannabis Telegram group here
View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

Widecells
September 28 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
picture of addict
November 16 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
scientist looking through microscope
April 12 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use